Biogen BIIB will report fourth-quarter and full-year 2024 results on Feb. 12, before market open. In the last reported ...

Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is ...

Cambridge-based biopharmaceutical company Sage Therapeutics filed a lawsuit against their partner, the biotechnology company ...

Biotech giant Biogen Inc (NASDAQ:BIIB) is scheduled to report fourth-quarter earnings on 12 February. The Wall Street ...

European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for ...

As it waits for its Alzheimer’s drug verdict, Biogen stumps up $1.5bn-plus upfront for rights to Sage drugs zuranolone for depression and SAGE-324 for essential tremor ...

Biogen is to call on the cutting-edge world of quantum computing to help speed up drug discovery. Quantum technology is one of the most exciting emerging developments in computing, and harnesses ...

The drug is also approved in China, Japan, Israel, Hong Kong, South Korea, the UAE and Great Britain. Biogen has developed Leqembi in collaboration with Eisai, with the latter leading the clinical ...

Biogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.

Also, concerns about the efficacy of both drugs was brought up by both FDA scientist and advisory committee members. OIG also noted that in the case of aducanumab, Biogen's meetings with the ...

Biogen and Eisai said they believe that EC's requests can be addressed with existing information, and that no new safety signals have been identified for Leqembi. The U.S. Food and Drug Administration ...

Any recommendations from EU's regulator must be accepted by the European Commission before the drug is made available ... Eisai and partner Biogen said in a joint statement.